Volume | 396,114 |
|
|||||
News | (1) | ||||||
Day High | 66.80 | Low High |
|||||
Day Low | 66.50 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Axonics Inc | AXNX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
66.50 | 66.50 | 66.80 | 66.64 | 66.47 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,340 | 396,114 | $ 66.68 | $ 26,414,365 | - | 47.59 - 69.68 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:11 | priorref | 557 | $ 66.64 | USD |
Axonics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.4B | 51.00M | - | 366.38M | -6.09M | -0.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Axonics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXNX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 67.33 | 67.49 | 66.42 | 66.84 | 691,694 | -0.69 | -1.02% |
1 Month | 68.90 | 69.67 | 66.42 | 67.94 | 1,021,163 | -2.26 | -3.28% |
3 Months | 68.50 | 69.67 | 66.42 | 67.99 | 904,996 | -1.86 | -2.72% |
6 Months | 52.88 | 69.68 | 48.30 | 65.63 | 994,815 | 13.76 | 26.02% |
1 Year | 60.32 | 69.68 | 47.59 | 61.35 | 825,566 | 6.32 | 10.48% |
3 Years | 61.94 | 79.915 | 38.41 | 61.37 | 651,391 | 4.70 | 7.59% |
5 Years | 19.66 | 79.915 | 15.25 | 53.45 | 590,719 | 46.98 | 238.96% |
Axonics Description
Axonics Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence. |